Cargando…
Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial
We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB–IIA) cervical cancer having risk factors after surgery. The condition was ass...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686219/ https://www.ncbi.nlm.nih.gov/pubmed/36422763 http://dx.doi.org/10.1007/s11684-021-0892-z |
_version_ | 1784835695970353152 |
---|---|
author | Weng, Danhui Xiong, Huihua Zhu, Changkun Wan, Xiaoyun Chen, Yaxia Wang, Xinyu Zhang, Youzhong Jiang, Jie Zhang, Xi Gao, Qinglei Chen, Gang Xing, Hui Wang, Changyu Li, Kezhen Chen, Yaheng Mao, Yuyan Hu, Dongxiao Pan, Zimin Chen, Qingqin Cui, Baoxia Song, Kun Yi, Cunjian Peng, Guangcai Han, Xiaobing An, Ruifang Fan, Liangsheng Wang, Wei Xiong, Tingchuan Chen, Yile Tang, Zhenzi Li, Lin Yang, Xingsheng Cheng, Xiaodong Lu, Weiguo Wang, Hui Kong, Beihua Xie, Xing Ma, Ding |
author_facet | Weng, Danhui Xiong, Huihua Zhu, Changkun Wan, Xiaoyun Chen, Yaxia Wang, Xinyu Zhang, Youzhong Jiang, Jie Zhang, Xi Gao, Qinglei Chen, Gang Xing, Hui Wang, Changyu Li, Kezhen Chen, Yaheng Mao, Yuyan Hu, Dongxiao Pan, Zimin Chen, Qingqin Cui, Baoxia Song, Kun Yi, Cunjian Peng, Guangcai Han, Xiaobing An, Ruifang Fan, Liangsheng Wang, Wei Xiong, Tingchuan Chen, Yile Tang, Zhenzi Li, Lin Yang, Xingsheng Cheng, Xiaodong Lu, Weiguo Wang, Hui Kong, Beihua Xie, Xing Ma, Ding |
author_sort | Weng, Danhui |
collection | PubMed |
description | We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB–IIA) cervical cancer having risk factors after surgery. The condition was assessed in terms of prognosis, adverse effects, and quality of life. This randomized trial involved nine centers across China. Eligible patients were randomized to receive adjuvant chemotherapy or CCRT after surgery. The primary end-point was progression-free survival (PFS). From December 2012 to December 2014, 337 patients were subjected to randomization. Final analysis included 329 patients, including 165 in the adjuvant chemotherapy group and 164 in the adjuvant CCRT group. The median follow-up was 72.1 months. The three-year PFS rates were both 91.9%, and the five-year OS was 90.6% versus 90.0% in adjuvant chemotherapy and CCRT groups, respectively. No significant differences were observed in the PFS or OS between groups. The adjusted HR for PFS was 0.854 (95% confidence interval 0.415–1.757; P = 0.667) favoring adjuvant chemotherapy, excluding the predefined non-inferiority boundary of 1.9. The chemotherapy group showed a tendency toward good quality of life. In comparison with post-operative adjuvant CCRT, adjuvant chemotherapy treatment showed non-inferior efficacy in patients with early-stage cervical cancer having pathological risk factors. Adjuvant chemotherapy alone is a favorable alternative post-operative treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available in the online version of this article at 10.1007/s11684-021-0892-z and is accessible for authorized users. |
format | Online Article Text |
id | pubmed-9686219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Higher Education Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96862192022-11-28 Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial Weng, Danhui Xiong, Huihua Zhu, Changkun Wan, Xiaoyun Chen, Yaxia Wang, Xinyu Zhang, Youzhong Jiang, Jie Zhang, Xi Gao, Qinglei Chen, Gang Xing, Hui Wang, Changyu Li, Kezhen Chen, Yaheng Mao, Yuyan Hu, Dongxiao Pan, Zimin Chen, Qingqin Cui, Baoxia Song, Kun Yi, Cunjian Peng, Guangcai Han, Xiaobing An, Ruifang Fan, Liangsheng Wang, Wei Xiong, Tingchuan Chen, Yile Tang, Zhenzi Li, Lin Yang, Xingsheng Cheng, Xiaodong Lu, Weiguo Wang, Hui Kong, Beihua Xie, Xing Ma, Ding Front Med Research Article We conducted a prospective study to assess the non-inferiority of adjuvant chemotherapy alone versus adjuvant concurrent chemoradiotherapy (CCRT) as an alternative strategy for patients with early-stage (FIGO 2009 stage IB–IIA) cervical cancer having risk factors after surgery. The condition was assessed in terms of prognosis, adverse effects, and quality of life. This randomized trial involved nine centers across China. Eligible patients were randomized to receive adjuvant chemotherapy or CCRT after surgery. The primary end-point was progression-free survival (PFS). From December 2012 to December 2014, 337 patients were subjected to randomization. Final analysis included 329 patients, including 165 in the adjuvant chemotherapy group and 164 in the adjuvant CCRT group. The median follow-up was 72.1 months. The three-year PFS rates were both 91.9%, and the five-year OS was 90.6% versus 90.0% in adjuvant chemotherapy and CCRT groups, respectively. No significant differences were observed in the PFS or OS between groups. The adjusted HR for PFS was 0.854 (95% confidence interval 0.415–1.757; P = 0.667) favoring adjuvant chemotherapy, excluding the predefined non-inferiority boundary of 1.9. The chemotherapy group showed a tendency toward good quality of life. In comparison with post-operative adjuvant CCRT, adjuvant chemotherapy treatment showed non-inferior efficacy in patients with early-stage cervical cancer having pathological risk factors. Adjuvant chemotherapy alone is a favorable alternative post-operative treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available in the online version of this article at 10.1007/s11684-021-0892-z and is accessible for authorized users. Higher Education Press 2022-11-23 2023 /pmc/articles/PMC9686219/ /pubmed/36422763 http://dx.doi.org/10.1007/s11684-021-0892-z Text en © Higher Education Press 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Research Article Weng, Danhui Xiong, Huihua Zhu, Changkun Wan, Xiaoyun Chen, Yaxia Wang, Xinyu Zhang, Youzhong Jiang, Jie Zhang, Xi Gao, Qinglei Chen, Gang Xing, Hui Wang, Changyu Li, Kezhen Chen, Yaheng Mao, Yuyan Hu, Dongxiao Pan, Zimin Chen, Qingqin Cui, Baoxia Song, Kun Yi, Cunjian Peng, Guangcai Han, Xiaobing An, Ruifang Fan, Liangsheng Wang, Wei Xiong, Tingchuan Chen, Yile Tang, Zhenzi Li, Lin Yang, Xingsheng Cheng, Xiaodong Lu, Weiguo Wang, Hui Kong, Beihua Xie, Xing Ma, Ding Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
title | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
title_full | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
title_fullStr | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
title_full_unstemmed | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
title_short | Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
title_sort | adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686219/ https://www.ncbi.nlm.nih.gov/pubmed/36422763 http://dx.doi.org/10.1007/s11684-021-0892-z |
work_keys_str_mv | AT wengdanhui adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT xionghuihua adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT zhuchangkun adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT wanxiaoyun adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT chenyaxia adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT wangxinyu adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT zhangyouzhong adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT jiangjie adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT zhangxi adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT gaoqinglei adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT chengang adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT xinghui adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT wangchangyu adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT likezhen adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT chenyaheng adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT maoyuyan adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT hudongxiao adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT panzimin adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT chenqingqin adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT cuibaoxia adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT songkun adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT yicunjian adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT pengguangcai adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT hanxiaobing adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT anruifang adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT fanliangsheng adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT wangwei adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT xiongtingchuan adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT chenyile adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT tangzhenzi adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT lilin adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT yangxingsheng adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT chengxiaodong adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT luweiguo adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT wanghui adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT kongbeihua adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT xiexing adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial AT mading adjuvantchemotherapyversusadjuvantconcurrentchemoradiotherapyafterradicalsurgeryforearlystagecervicalcancerarandomizednoninferioritymulticentertrial |